These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 1855278)

  • 1. Unaltered pharmacokinetics after the administration of high-dose etoposide without prior dilution.
    Ehninger G; Proksch B; Schmidt H; Waidelich P; Eichel B; Dopfer R
    Cancer Chemother Pharmacol; 1991; 28(3):214-6. PubMed ID: 1855278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors influencing the haematological recovery after allogeneic bone marrow transplantation in leukaemia patients treated with methotrexate-containing GVHD prophylaxis: a single-centre experience.
    Hassan HT; Krog C; Stockschläder M; Schleimer B; Zeller W; Krüger W; Erttmann R; Zander AR
    Anticancer Res; 1997; 17(1B):589-99. PubMed ID: 9066585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pharmacokinetics and toxicity of two application schedules with high-dose VP-16 in patients receiving an allogeneic bone marrow transplantation.
    Mross K; Reifke J; Bewermeier P; Kruger W; Hossfeld DK; Zander A
    Ann Oncol; 1996 Jan; 7(1):83-8. PubMed ID: 9081397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
    Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
    J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioavailability and pharmacokinetic features of etoposide in childhood acute lymphoblastic leukemia patients.
    Chen CL; Rawwas J; Sorrell A; Eddy L; Uckun FM
    Leuk Lymphoma; 2001 Jul; 42(3):317-27. PubMed ID: 11699396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of high-dose etoposide administered in combination with fractionated total-body irradiation as conditioning for allogeneic hematopoietic stem cell transplantation in children with acute lymphoblastic leukemia.
    Chrzanowska M; Sobiak J; Grund G; Wachowiak J
    Pediatr Transplant; 2011 Feb; 15(1):96-102. PubMed ID: 21159109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone marrow transplantation for advanced acute leukemia: a pilot study of high-energy total body irradiation, cyclophosphamide and continuous infusion etoposide.
    Bostrom B; Weisdorf DJ; Kim T; Kersey JH; Ramsay NK
    Bone Marrow Transplant; 1990 Feb; 5(2):83-9. PubMed ID: 2107007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of undiluted or diluted high-dose etoposide with or without busulfan administered to patients with hematologic malignancies.
    Mross K; Bewermeier P; Krüger W; Stockschläder M; Zander A; Hossfeld DK
    J Clin Oncol; 1994 Jul; 12(7):1468-74. PubMed ID: 8021738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-energy total body irradiation as preparation for bone marrow transplantation in leukemia patients: treatment technique and related complications.
    Bradley J; Reft C; Goldman S; Rubin C; Nachman J; Larson R; Hallahan DE
    Int J Radiat Oncol Biol Phys; 1998 Jan; 40(2):391-6. PubMed ID: 9457826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Less intense conditioning with fludarabine, cyclophosphamide, idarubicin and etoposide (FCIE) followed by allogeneic unselected peripheral blood stem cell transplantation in elderly patients with leukemia.
    Schlenk RF; Hartmann F; Hensel M; Jung W; Weber-Nordt R; Gabler A; Haas R; Ho AD; Trümper L; Döhner H
    Leukemia; 2002 Apr; 16(4):581-6. PubMed ID: 11960336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I trial of carboplatin and etoposide given as continuous infusions to adults with leukemia.
    Lee EJ; Reck K; Carter C; Hodges S; Schiffer CA
    Leukemia; 1993 Oct; 7(10):1500-3. PubMed ID: 8412310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose cyclophosphamide, carmustine, and etoposide followed by allogeneic bone marrow transplantation in patients with lymphoid malignancies who had received prior dose-limiting radiation therapy.
    Demirer T; Weaver CH; Buckner CD; Petersen FB; Bensinger WI; Sanders J; Clift RA; Lilleby K; Anasetti C; Martin P
    J Clin Oncol; 1995 Mar; 13(3):596-602. PubMed ID: 7884421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Donor buffy-coat infusion and chemotherapy for leukemia in relapse after marrow transplantation.
    Bogdanić V; Aurer I; Hitrec V; Boban D; Nemet D; Zupancić-Salek S; Labar B
    Haematologica; 1995; 80(4):338-40. PubMed ID: 7590504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of high-dose etoposide after short-term infusion.
    Köhl P; Köppler H; Schmidt L; Fritsch HW; Holz J; Pflüger KH; Jungclas H
    Cancer Chemother Pharmacol; 1992; 29(4):316-20. PubMed ID: 1537079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and bioequivalence of etoposide following intravenous administration of etoposide phosphate and etoposide in patients with solid tumors.
    Kaul S; Igwemezie LN; Stewart DJ; Fields SZ; Kosty M; Levithan N; Bukowski R; Gandara D; Goss G; O'Dwyer P
    J Clin Oncol; 1995 Nov; 13(11):2835-41. PubMed ID: 7595746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic comparison of oral and intravenous etoposide in patients treated with the CHOEP-regimen for malignant lymphomas.
    Kroschinsky FP; Friedrichsen K; Mueller J; Pursche S; Haenel M; Prondzinsky R; Ehninger G; Schleyer E
    Cancer Chemother Pharmacol; 2008 Apr; 61(5):785-90. PubMed ID: 17579865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Société Française de Greffe de Moelle.
    Blaise D; Kuentz M; Fortanier C; Bourhis JH; Milpied N; Sutton L; Jouet JP; Attal M; Bordigoni P; Cahn JY; Boiron JM; Schuller MP; Moatti JP; Michallet M
    J Clin Oncol; 2000 Feb; 18(3):537-46. PubMed ID: 10653869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of high-dose etoposide phosphate in man.
    Fields SZ; Budman DR; Young RR; Kreis W; Ingram R; Schulman P; Cherny RC; Wright J; Behr J; Snow C; Schacter LP
    Bone Marrow Transplant; 1996 Nov; 18(5):851-6. PubMed ID: 8932836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intensified conditioning regimen in bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Kröger N; Krüger W; Wacker-Backhaus G; Hegewisch-Becker S; Stockschläder M; Fuchs N; Rüssmann B; Renges H; Dürken M; Bielack S; de Wit M; Schuch G; Bartels H; Braumann D; Kuse R; Kabisch H; Erttmann R; Zander AR
    Bone Marrow Transplant; 1998 Dec; 22(11):1029-33. PubMed ID: 9877263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I and pharmacodynamic study of sequential topotecan and etoposide in patients with relapsed or refractory acute myelogenous and lymphoblastic leukemia.
    Cooper BW; Donaher E; Lazarus HM; Green SB; Gosky DM; Rosenthal NS; Berger SJ; Li X; Ingalls ST; Hoppel CL; Gerson SL
    Leuk Res; 2003 Jan; 27(1):35-44. PubMed ID: 12479850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.